Xenco Medical Expands its Ambulatory Surgery Center Device Portfolio with FDA Clearance and Launch of its Multilevel CerviKit

Xenco Medical has expanded its ASC surgical device portfolio through the FDA clearance and launch of its Multilevel CerviKitTM, an expansion of Xenco Medical’s breakthrough single-use cervical spine technology to include a comprehensive suite of implants and single-use instruments for 2, 3, and 4 level anterior cervical spine procedures.

Optimized for the ambulatory surgery center setting, the Multilevel CerviKit builds on Xenco Medical’s existing portfolio of disposable spinal implant and instrument platforms included in its ASC CerviKit and adds to its portfolio of single-use lumbar surgical devices. The cervical plating options included in the Multilevel CerviKit feature an optimally thin profile, an intuitive locking mechanism, and a dual textured surface for thorough fixation.

The surgical platform is a sterile-packaged, single-use system designed to enhance intraoperative efficiency. Matched with a disposable delivery instrument and coupled with corresponding, single-use surgical instruments, the Multilevel CerviKit is engineered to complement Xenco Medical’s existing portfolio of single-use spinal systems.

Developed at the intersection of materials science and mechanical engineering, the highly reinforced, composite polymer instruments included with each of Xenco Medical’s multilevel anterior cervical plates allow for both consistent mechanical performance and the elimination of the costly logistics associated with the autoclave process. By expanding Xenco Medical’s current ASC portfolio, the Multilevel CerviKit is designed to strengthen an ambulatory surgery center’s ability to overcome sterilization bottlenecks while providing optimal care.

“As COVID-19 spurred increased demand for sterile-packaged, single-use spinal platforms and accelerated growth in the volume of outpatient cervical spine procedures, we have bolstered our commitment to expanding access to safer, streamlined surgical procedures through the launch of our single-use Multilevel CerviKit,” said Xenco Medical Founder and CEO Jason Haider.

Designed to be easily transportable, each Xenco Medical spinal system has been designed for both surgical performance and logistical efficiency. Unlike traditional instruments that are reused in hundreds of patients until a mechanical failure, the disposable Xenco Medical spinal implant systems are optimally calibrated and sterile-packaged for individual use. The product of advanced materials science, Xenco Medical’s single-use spinal implant systems are designed to be compatible with the company’s intelligent surgical vending machines and can be trained on using Xenco Medical’s glasses-free holographic surgical simulation platform.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”